422 related articles for article (PubMed ID: 31721169)
21. Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer.
Su Y; Yamazaki S; Morisue R; Suzuki J; Yoshikawa T; Nakatsura T; Tsuboi M; Ochiai A; Ishii G
Pathobiology; 2021; 88(3):218-227. PubMed ID: 33321503
[TBL] [Abstract][Full Text] [Related]
22. Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy.
Lee J; Han Y; Wang W; Jo H; Kim H; Kim S; Yang KM; Kim SJ; Dhanasekaran DN; Song YS
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439774
[TBL] [Abstract][Full Text] [Related]
23. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
24. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
25. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection.
Sperk M; Domselaar RV; Neogi U
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987244
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
Xu HH; Gan J; Xu DP; Li L; Yan WH
Front Immunol; 2021; 12():614773. PubMed ID: 34276642
[TBL] [Abstract][Full Text] [Related]
28. Expression of immune checkpoints in T cells of esophageal cancer patients.
Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H
Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071
[TBL] [Abstract][Full Text] [Related]
29. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Implications of Immune Infiltrates in the Breast Cancer Microenvironment: The Role of Expressions of CTLA-4, PD-1, and LAG-3.
Bagbudar S; Karanlik H; Cabioglu N; Bayram A; Ibis K; Aydin E; Yavuz E; Onder S
Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):99-107. PubMed ID: 34608875
[TBL] [Abstract][Full Text] [Related]
31. Expression level of immune checkpoint inhibitory factors in preeclampsia.
Madadi S; Mohammadinejad S; Alizadegan A; Hojjat-Farsangi M; Dolati S; Samadi Kafil H; Jadidi-Niaragh F; Soltani-Zangbar MS; Motavalli R; Etemadi J; Eghbal-Fard S; Aghebati-Maleki L; Danaii S; Taghavi S; Yousefi M
Hum Immunol; 2022; 83(8-9):628-636. PubMed ID: 35906120
[TBL] [Abstract][Full Text] [Related]
32. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
Ann Oncol; 2017 Dec; 28(12):2977-2984. PubMed ID: 29045526
[TBL] [Abstract][Full Text] [Related]
33. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
[TBL] [Abstract][Full Text] [Related]
34. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
35. Elevated T cell activation score is associated with improved survival of breast cancer.
Lu L; Bai Y; Wang Z
Breast Cancer Res Treat; 2017 Aug; 164(3):689-696. PubMed ID: 28488141
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
37. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
38. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
[TBL] [Abstract][Full Text] [Related]
39. Lymphocyte-activation gene-3, an important immune checkpoint in cancer.
He Y; Rivard CJ; Rozeboom L; Yu H; Ellison K; Kowalewski A; Zhou C; Hirsch FR
Cancer Sci; 2016 Sep; 107(9):1193-7. PubMed ID: 27297395
[TBL] [Abstract][Full Text] [Related]
40. On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment.
Tundo GR; Sbardella D; Lacal PM; Graziani G; Marini S
Chemotherapy; 2019; 64(2):62-80. PubMed ID: 31387102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]